Tvardi Therapeutics (TVRD) Earnings Analysis

Tvardi Therapeutics (TVRD) next reports earnings on 2026-08-13, consensus EPS -0.70444 USD. Last quarter (2026-05-08) it missed with EPS -0.73 USD vs -0.65 USD est (-12.3%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -1.74.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TVRD next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.70444 USD
Revenue estimaten/a

TVRD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-0.73 USD-0.65 USD-12.3%Miss
2026-03-31-0.78 USD-0.55 USD-41.8%Miss
2025-11-13-0.59 USD-0.83 USD+28.9%Beat
2025-08-14-1 USD-0.51 USD-96.1%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

TVRD valuation and analyst view

Trailing P/E-1.74
Trailing EPS-1.64571 USD
Price / book1.79
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (2 buy / 1 hold / 1 sell)
Avg price target10.67 USD

Related research pages

Frequently asked questions

When is Tvardi Therapeutics (TVRD)'s next earnings date?

Tvardi Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.70444 USD.

Did TVRD beat earnings last quarter?

In its 2026-05-08 report, TVRD posted EPS of -0.73 USD versus a -0.65 USD estimate — a miss of 12.3%.

What is TVRD's earnings track record?

Over the last 4 reported quarters with consensus data, TVRD beat estimates 1 times (25%).

What is TVRD's current P/E ratio and EPS?

TVRD trades at a trailing P/E of -1.74 on trailing EPS of -1.645713023634993 USD.

What do analysts rate TVRD?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 10.67 USD.